Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part ...
(MENAFN- GlobeNewsWire - Nasdaq) New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results